Relapsing forms of Multiple Sclerosis
Showing 1 - 25 of >10,000
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Relapsing Forms of Multiple Sclerosis Trial (BIIB091, DRF, Placebo)
Not yet recruiting
- Relapsing Forms of Multiple Sclerosis
- BIIB091
- +2 more
- (no location specified)
Mar 23, 2023
Multiple Sclerosis Trial (Dimethyl fumarate)
Not yet recruiting
- Multiple Sclerosis
- Dimethyl fumarate
- (no location specified)
Dec 12, 2022
Ocrelizumab and Ofatumumab Administration in Relapsing Multiple
Completed
- Relapsing Forms of Multiple Sclerosis
-
Lutherville, Maryland
- +1 more
Oct 19, 2022
Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)
Completed
- Multiple Sclerosis
- temelimab 18 mg/kg
- +3 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)
Recruiting
- Relapsing Forms of Multiple Sclerosis
- EHP-101 25 mg OD
- +3 more
-
Cullman, Alabama
- +3 more
Apr 29, 2022
Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- Ublituximab
-
Pasadena, California
- +7 more
Aug 19, 2022
Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)
Completed
- Multiple Sclerosis
- Blood draw for future biomarker analysis
-
Los Angeles, CaliforniaInvestigational Site Number 8400001
Mar 15, 2022
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial
Active, not recruiting
- Secondary Progressive Multiple Sclerosis
- +2 more
- ACTH
- Placebo
-
Minneapolis, Minnesota
- +2 more
Mar 29, 2022
Relapsing Forms of Multiple Sclerosis Trial in China, Japan (Diroximel fumarate)
Recruiting
- Relapsing Forms of Multiple Sclerosis
- Diroximel fumarate
-
Tianjin, China
- +23 more
Jul 22, 2022
Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)
Terminated
- Multiple Sclerosis
- Temelimab 18 mg/kg
- +2 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Multiple Sclerosis, Relapsing-Remitting Trial in Canada, United States (23-PPV, 13-PCV Booster, Influenza Vaccine)
Completed
- Multiple Sclerosis, Relapsing-Remitting
- 23-PPV
- +5 more
-
Cullman, Alabama
- +21 more
Apr 4, 2022
Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)
Recruiting
- Relapsing Multiple Sclerosis
-
Boston, MassachusettsPartners MS Center, 60 Fenwood Road
Jul 20, 2021
Multiple Sclerosis Trial in Newark (Betaseron, Copaxone)
Completed
- Multiple Sclerosis
-
Newark, New JerseyNew Jersey Medical School
Oct 18, 2021
Relapsing Multiple Sclerosis, Multiple Sclerosis Trial (Placebo, Pirtobrutinib)
Not yet recruiting
- Relapsing Multiple Sclerosis
- Multiple Sclerosis
- Placebo
- Pirtobrutinib
- (no location specified)
Oct 24, 2023
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Montpellier (Neuropsychological assessment,
Terminated
- Progressive Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Neuropsychological assessment
- +2 more
-
Montpellier, FranceHopital Gui de Chauliac -Service de Neurologie
May 14, 2021
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular
Recruiting
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Tetanus, diphtheria, and acellular pertussis vaccine
- +2 more
-
Palo Alto, California
- +47 more
Jun 24, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib)
Recruiting
- Relapsing Multiple Sclerosis
-
Beijin, ChinaPeking University Third Hospital
Jul 6, 2021
Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)
Completed
- Multiple Sclerosis
-
Aurora, ColoradoUniversity of Colorado Hospital
Jul 1, 2021
Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Not yet recruiting
- Relapsing Multiple Sclerosis
- No intervention
- (no location specified)
Nov 16, 2023
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
-
Phoenix, Arizona
- +12 more
Nov 11, 2021
Multiple Sclerosis, Relapsing-Remitting Trial in Elazig (Reiki)
Recruiting
- Multiple Sclerosis, Relapsing-Remitting
- Reiki
-
Elazıg, TurkeyFirat University
Nov 8, 2023